ATE535535T1 - Methoden für die diagnose von demenz und anderen neurologischen erkrankungen - Google Patents

Methoden für die diagnose von demenz und anderen neurologischen erkrankungen

Info

Publication number
ATE535535T1
ATE535535T1 AT07710657T AT07710657T ATE535535T1 AT E535535 T1 ATE535535 T1 AT E535535T1 AT 07710657 T AT07710657 T AT 07710657T AT 07710657 T AT07710657 T AT 07710657T AT E535535 T1 ATE535535 T1 AT E535535T1
Authority
AT
Austria
Prior art keywords
patient
alzheimer
disease dementia
accurate mass
methods
Prior art date
Application number
AT07710657T
Other languages
English (en)
Inventor
Lisa Cook
Dayan Goodenowe
Original Assignee
Phenomenome Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomenome Discoveries Inc filed Critical Phenomenome Discoveries Inc
Application granted granted Critical
Publication of ATE535535T1 publication Critical patent/ATE535535T1/de

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/10Phosphatides, e.g. lecithin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/10Phosphatides, e.g. lecithin
    • C07F9/106Adducts, complexes, salts of phosphatides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N37/00Details not covered by any other group of this subclass
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/62Detectors specially adapted therefor
    • G01N30/72Mass spectrometers
    • G01N30/7233Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/16Phosphorus containing
    • Y10T436/163333Organic [e.g., chemical warfare agents, insecticides, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Primary Health Care (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Electrochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07710657T 2006-02-28 2007-02-28 Methoden für die diagnose von demenz und anderen neurologischen erkrankungen ATE535535T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77729006P 2006-02-28 2006-02-28
US80477906P 2006-06-14 2006-06-14
US88888307P 2007-02-08 2007-02-08
PCT/CA2007/000313 WO2007098585A1 (en) 2006-02-28 2007-02-28 Methods for the diagnosis of dementia and other neurological disorders

Publications (1)

Publication Number Publication Date
ATE535535T1 true ATE535535T1 (de) 2011-12-15

Family

ID=38458611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07710657T ATE535535T1 (de) 2006-02-28 2007-02-28 Methoden für die diagnose von demenz und anderen neurologischen erkrankungen

Country Status (11)

Country Link
US (2) US8304246B2 (de)
EP (3) EP2851369A3 (de)
JP (3) JP5496513B2 (de)
KR (1) KR20080104350A (de)
AT (1) ATE535535T1 (de)
AU (1) AU2007219666A1 (de)
CA (2) CA2689848A1 (de)
HK (1) HK1208467A1 (de)
IL (1) IL193426A0 (de)
NZ (1) NZ570413A (de)
WO (1) WO2007098585A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095275A1 (en) 2007-02-08 2008-08-14 Phenomenome Discoveries Inc. Methods for the treatment of senile dementia of the alzheimer's type
US20100105101A1 (en) 2007-04-13 2010-04-29 Phenomenome Discoveries Inc. Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging
SG182971A1 (en) * 2007-07-26 2012-08-30 Phenomenome Discoveries Inc Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders
KR20180090396A (ko) 2008-01-18 2018-08-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
US9965035B2 (en) 2008-05-13 2018-05-08 Apple Inc. Device, method, and graphical user interface for synchronizing two or more displays
US9121844B1 (en) * 2008-09-09 2015-09-01 Sociedad Europea de Analisis Diferencial de Movilidad Method to analyze and classify persons and organisms based on odor patterns from released vapors
TWI475989B (zh) 2008-12-22 2015-03-11 Phenomenome Discoveries Inc 縮醛磷脂類化合物,含彼之醫藥組成物以及治療老化疾病的方法
EP2770328B1 (de) 2009-10-01 2017-12-27 Phenomenome Discoveries Inc. Verfahren zur Diagnose von Bauchspeicheldrüsenkrebs
AU2011280944A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting diseases or conditions using phagocytic cells
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
MX382244B (es) 2010-07-23 2025-03-13 Harvard College Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
WO2012090625A1 (ja) * 2010-12-28 2012-07-05 医療法人社団ブックス 認知症を血液サンプルで判定するための検査方法
AU2012321071B2 (en) * 2011-11-17 2015-02-26 Med-Life Discoveries Lp Methods for the synthesis of 13C labeled plasmalogen
WO2013119651A1 (en) * 2012-02-08 2013-08-15 Nestec Sa Methods for diagnosing cognitive impairment
US20150031572A1 (en) * 2012-02-15 2015-01-29 Basf Se Means and methods for assessing neuronal toxicity
EP2831782A2 (de) * 2012-03-29 2015-02-04 Koninklijke Philips N.V. System und verfahren zur verbesserung des behandlungsworkflows von morbus alzheimer durch neurologen
US20140179805A1 (en) 2012-06-15 2014-06-26 Harry Stylli Methods of detecting diseases or conditions
SG11201408383SA (en) 2012-06-15 2015-01-29 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
EP2965086A4 (de) 2013-03-09 2017-02-08 Harry Stylli Verfahren zum nachweis von prostatakrebs
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014197339A1 (en) * 2013-06-08 2014-12-11 Apple Inc. Device, method, and graphical user interface for synchronizing two or more displays
JP6495902B2 (ja) * 2013-11-14 2019-04-03 ネステク ソシエテ アノニム 健康的な加齢に関係する脂質バイオマーカー
WO2015138879A1 (en) * 2014-03-13 2015-09-17 Massachusetts Institute Of Technology Compositions containing pufa, uridine and choline and methods of use thereof
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
US10006925B2 (en) 2016-05-30 2018-06-26 Universal Diagnostics, S. L. Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
GB201611596D0 (en) * 2016-07-04 2016-08-17 British American Tobacco Investments Ltd Apparatus and method for classifying a tobacco sample into one of a predefined set of taste categories
US20200241011A1 (en) * 2017-02-24 2020-07-30 Mattias ARNOLD Compositions and methods related to sex- specific metabolic drivers in alzheimers disease
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US20190385711A1 (en) 2018-06-19 2019-12-19 Ellipsis Health, Inc. Systems and methods for mental health assessment
JP7608171B2 (ja) 2018-06-19 2025-01-06 エリプシス・ヘルス・インコーポレイテッド 精神的健康評価のためのシステム及び方法
US12029579B2 (en) * 2018-07-13 2024-07-09 Pst Inc. Apparatus for estimating mental/neurological disease
EP3849410A4 (de) 2018-09-14 2022-11-02 Neuroenhancement Lab, LLC System und verfahren zur verbesserung des schlafs
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
WO2022263927A2 (en) * 2021-06-17 2022-12-22 Phoska Biopharma Pte. Ltd. Plasmalogen derivatives and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009371A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
US5731354A (en) 1996-05-06 1998-03-24 Clarion Pharmaceuticals Inc. Treatment for the inhibition of neuro-degenerative disease states
US6177476B1 (en) 1998-08-27 2001-01-23 Clarion Pharmaceuticals Inc. Nutritional supplements for replenishing plasmalogens
CA2298181C (en) 2000-02-02 2006-09-19 Dayan Burke Goodnough Non-targeted complex sample analysis
EP2330219A3 (de) 2000-04-14 2011-11-23 Metabolon, Inc. Verfahren zur Arzneimittelentdeckung, Krankheitsbehandlung und Diagnose mithilfe eines Metaboloms
AU2001286059A1 (en) 2000-09-08 2002-03-22 Oxford Glycosciences (Uk) Ltd. Automated identification of peptides
DE10291524D2 (de) * 2001-04-06 2004-07-01 Anker Thorsten Verfahren zum Nachweis chronisch-demenzieller Erkrankungen, zugehörige Peptide und Nachweisreagenzien
AU2002341488A1 (en) * 2001-05-09 2002-11-18 Biovision Ag Method for detecting progredient chronic dementia, and associated peptides and detection reagents
EP2221620B1 (de) * 2002-08-23 2013-10-02 Bayer Pharma Aktiengesellschaft Biomarker zur Diagnose von Alzheimer
EP1694816B1 (de) * 2003-11-07 2013-08-28 Ciphergen Biosystems, Inc. Biomarker für morbus alzheimer
WO2005085838A2 (en) * 2004-03-02 2005-09-15 Vanderbilt University Computational analysis of mass spectroscopic lipid data
WO2005116659A2 (en) * 2004-05-18 2005-12-08 Neurodx, Llc Compositions and methods relating to alzheimer’s disease
JP4176749B2 (ja) * 2005-07-29 2008-11-05 学校法人帝京大学 疾病検査法
US8026099B2 (en) * 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders

Also Published As

Publication number Publication date
JP2009528517A (ja) 2009-08-06
EP1922325B1 (de) 2011-11-30
HK1113160A1 (en) 2008-09-26
US20130110408A1 (en) 2013-05-02
HK1208467A1 (en) 2016-03-04
NZ570413A (en) 2011-07-29
CA2689848A1 (en) 2007-09-07
US8304246B2 (en) 2012-11-06
WO2007098585A1 (en) 2007-09-07
JP2012255793A (ja) 2012-12-27
AU2007219666A1 (en) 2007-09-07
EP2851369A3 (de) 2015-06-17
JP5496513B2 (ja) 2014-05-21
IL193426A0 (en) 2009-05-04
EP2322531A2 (de) 2011-05-18
EP1922325A4 (de) 2009-05-27
CA2640748A1 (en) 2007-09-07
EP1922325A1 (de) 2008-05-21
KR20080104350A (ko) 2008-12-02
CA2640748C (en) 2010-04-20
EP2851369A2 (de) 2015-03-25
US20100003761A1 (en) 2010-01-07
JP2014197018A (ja) 2014-10-16
EP2322531A3 (de) 2011-09-07

Similar Documents

Publication Publication Date Title
ATE535535T1 (de) Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
Edler et al. Aged chimpanzees exhibit pathologic hallmarks of Alzheimer's disease
BRPI0516674A (pt) método de análise de mal de alzheimer e reagente de diagnóstico
DE60332538D1 (de) Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen
BRPI0112262B8 (pt) processo para detecção e teste para um marcador de uma doença conformacional, kit, processo para identificar um composto, processo para detectar a presença de uma forma patogênica prp sc de proteína de príon, e aparelho
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
WO2005042761A3 (en) Biomarkers for amyotrophic lateral sclerosis
WO2021067850A3 (en) METHODS OF DETECTING circRNA
ATE475888T1 (de) Biomarker zur diagnose von alzheimer
DE602006015281D1 (de) Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
DE60326153D1 (de) Verfahren zur diagnose von morbus alzheimer
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
EP2672266A3 (de) Verfahren zum Screening einer Lungen-Transplantation Kandidat für ein erhöhtes Risiko einer Abstoßung
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
DK1664793T3 (da) Neurotoksisk aminosyre eller neurotoksisk derivat deraf forbundet med neurologiske lidelser
EP1600513A4 (de) Verfahren zur untersuchung einer zelle
ATE465408T1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
ATE483982T1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
EP2338988A4 (de) Beurteilungs-/screeningverfahren für erkrankungen in zusammenhang mit d-aminosäure mittels dao1-/-maus
ATE470152T1 (de) Diagnostikverfahren mittels messungen der antiglykan-antikörper-spiegeln
Klunk et al. Small molecule beta-amyloid probes which distinguish homogenates of Alzheimer's and control brains
BR0209681A (pt) Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente
DE60235576D1 (de) Diagnostikum für die frühe phase von morbus alzheimer
Klunk et al. Quantitative in vitro NMR analysis of Alzheimer's, non-Alzheimer's demented and control brain
ATE509270T1 (de) Aus blutplättchen gewonnene mikropartikel als neue diagnosemarker für eine herz-kreislauf- erkrankung